Uğur O, Serdengeçti M, Karacalioğlu O, Ergün E L, Peksoy I, Cekirge S
Department of Nuclear Medicine, Hacettepe University Medical School, Ankara, Turkey.
Ann Nucl Med. 1999 Apr;13(2):77-81. doi: 10.1007/BF03164881.
The aim of the present study was to assess the predictive value of captopril scintigraphy with the new renal agent 99mTc-ethylenedicysteine (99mTc-EC) for post-interventional improvement in blood pressure. Twelve patients who had persistently high blood pressure with previous demonstration of various degrees of renal artery lesion on angiography were included into the study. Baseline and captopril scintigraphies were performed on the same day at 4 hour intervals after the injection of 74 and 296 MBq of 99mTc-EC, respectively. All patients had percutaneous transluminal angioplasty (PTA), and improvement in blood pressure was evaluated 3-6 months after the intervention. 99mTc-EC captopril scintigraphy successfully predicted a positive or negative outcome in 11 of 12 patients. In one patient with captopril induced renal function deterioration, scintigraphy failed to predict post-interventional response. Our preliminary findings showed that 99mTc-EC captopril scintigraphy can be used to determine patients who will benefit from revascularization.
本研究的目的是评估使用新型肾显像剂99m锝-乙二半胱氨酸（99mTc-EC）的卡托普利闪烁扫描术对介入治疗后血压改善情况的预测价值。研究纳入了12例持续高血压患者，这些患者之前的血管造影显示有不同程度的肾动脉病变。分别在注射74和296MBq的99mTc-EC后，于同一天每隔4小时进行一次基线和卡托普利闪烁扫描。所有患者均接受了经皮腔内血管成形术（PTA），并在干预后3至6个月评估血压改善情况。99mTc-EC卡托普利闪烁扫描术成功预测了12例患者中11例的阳性或阴性结果。在1例卡托普利导致肾功能恶化的患者中，闪烁扫描未能预测介入治疗后的反应。我们的初步研究结果表明，99mTc-EC卡托普利闪烁扫描术可用于确定将从血运重建中获益的患者。
